SCHEMBL3417634

SCHEMBL3417634

Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@H]1CO

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 4/20 0.75
PI4KA P42356 2/20 0.75
PI4K2B Q8TCG2 2/20 0.75
PI4K2A Q9BTU6 2/20 0.75
PI4KB Q9UBF8 2/20 0.75
ADORA1 P30542 2/20 0.75
DPP4 P27487 1/20 0.75
MEN1 O00255 1/20 0.75
SLC28A1 O00337 1/20 0.75
MAP3K7 O43318 1/20 0.75
SLC28A2 O43868 1/20 0.75
GAPDH P04406 1/20 0.75
MAPK1 P28482 1/20 0.75
ADORA2A P29274 1/20 0.75
ADORA2B P29275 1/20 0.75
STAT6 P42226 1/20 0.75
KMT2A Q03164 1/20 0.75
SMN1; SMN2 Q16637 1/20 0.75
DOT1L Q8TEK3 1/20 0.75
SLC29A1 Q99808 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3417640 1.00 ADORA3 (0.75) ADORA3PI4KAPI4K2BPI4K2API4KB
SCHEMBL8888273 0.92 ADORA3 (0.72) ADORA3PI4KAPI4K2BPI4K2API4KB
SCHEMBL8888270 0.92 ADORA3 (0.72) ADORA3PI4KAPI4K2BPI4K2API4KB
SCHEMBL8888538 0.92 ADORA3 (0.72) ADORA3PI4KAPI4K2BPI4K2API4KB
SCHEMBL23813581 0.91 ADORA3 (0.82) ADORA3PI4KAPI4K2BPI4K2API4KB
SCHEMBL17198348 0.91 ADORA3 (0.82) ADORA3PI4KAPI4K2BPI4K2API4KB
SCHEMBL9140587 0.91 ADORA3 (0.70) ADORA3PI4KAPI4K2BPI4K2API4KB
SCHEMBL9146345 0.91 ADORA3 (0.70) ADORA3PI4KAPI4K2BPI4K2API4KB
SCHEMBL9146357 0.91 ADORA3 (0.70) ADORA3PI4KAPI4K2BPI4K2API4KB
SCHEMBL9140578 0.91 ADORA3 (0.70) ADORA3PI4KAPI4K2BPI4K2API4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025128741-A1 OCTADECANOID COMPOSITIONS AND METHODS OF ACTIVATING MUCOSAL REPAIR PATHWAYS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-06-19 WO disclosed
CN-114836399-B Process for preparing isoguanine deoxyribonucleotide 天津大学 2024-07-05 CN disclosed
CN-118001425-A Preparation method and application of nanoparticle capable of targeting brain injury part for traumatic brain injury treatment 上海市第六人民医院 2024-05-10 CN disclosed
US-11959065-B2 Bacillus megaterium bioactive compositions and metabolites PRO FARM GROUP, INC. (US) 2024-04-16 US disclosed
US-20230142126-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES HEALION BIO., INC. (US) 2023-05-11 US disclosed
EP-4149552-A1 COMPOSITIONS AND METHODS FOR INCREASING EFFICACY OF A DRUG Healion Bio, Inc. (US) 2023-03-22 EP disclosed
US-20220315885-A1 BACILLUS MEGATERIUM BIOACTIVE COMPOSITIONS AND METABOLITES MARRONE BIO INNOVATIONS, INC. (US) 2022-10-06 US disclosed
CN-114836399-A Preparation method of isoguanine deoxyribonucleotide 天津大学 2022-08-02 CN disclosed
CN-114836400-A Enzyme participating in synthesis of bacteriophage diaminopurine and application thereof 天津大学 2022-08-02 CN disclosed
WO-2022152192-A1 ENZYME INVOLVED IN PHAGE DIAMINOPURINE SYNTHESIS, AND USE THEREOF 天津大学 2022-07-21 WO disclosed
US-7351827-B2 Substituted oxetanes, method of making, and method of use thereof THE UNIVERSITY OF CONNECTICUT (US) 2008-04-01 US disclosed
US-7214668-B2 Phosphonic acid based prodrugs of PMEA and its analogues METABASIS THERAPEUTICS, INC. (US) 2007-05-08 US disclosed
EP-1532157-A2 NOVEL PHOSPHONIC ACID BASED PRODRUGS OF PMEA AND ITS ANALOGUES Metabasis Therapeutics, Inc. (US) 2005-05-25 EP disclosed
WO-2004037161-A2 CYCLIC PRODRUGS OF PMEA ONE OF ITS ANALOGUES METABASIS THERAPEUTICS, INC. (US) 2004-05-06 WO disclosed
US-20030229225-A1 Novel phosphonic acid based prodrugs of PMEA and its analogues METABASIS THERAPEUTICS, INC. 2003-12-11 US disclosed
US-5597824-A VIRICIDES ABBOTT LABORATORIES (US) 1997-01-28 US disclosed
US-5420276-A Ring contraction via diazoketone intermediate, active against herpes ABBOTT LABORATORIES (US) 1995-05-30 US disclosed
EP-0292588-B1 NOVEL COMPOUND HAVING HYPOXANTHINE BASE,ITS USE AND PROCESS FOR PRODUCING IT NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1992-04-01 EP disclosed
EP-0433898-A2 Analogs of oxetanyl purines and pyrimidines ABBOTT LABORATORIES (US) 1991-06-26 EP disclosed
US-4845215-A VIRICIDE, IMMUNOSUPPRESANT NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1989-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230142126-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES CTSV, CTSB, CTSS ADORA3 3416/4885PI4KA 2121/4885PI4K2B 2189/4885
US-20030229225-A1 Novel phosphonic acid based prodrugs of PMEA and its analogues MTAP, PNP, MPO ADORA3 115/4885PI4KA 811/4885PI4K2B 714/4885
US-11959065-B2 Bacillus megaterium bioactive compositions and metabolites GZMB, VIP, BAX ADORA3 4282/4885PI4KA 1375/4885PI4K2B 587/4885
US-20220315885-A1 BACILLUS MEGATERIUM BIOACTIVE COMPOSITIONS AND METABOLITES GZMB, VIP, BAX ADORA3 4282/4885PI4KA 1375/4885PI4K2B 587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.